This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.

Researchers from National Taiwan University Hospital and Academia Sinica have identified a simple blood marker that can reliably pinpoint chronic hepatitis B (CHB) patients at negligible risk of ...

The XGBoost-based approach demonstrated robust external validation across multiple centers, supporting clinical adoption to guide personalized treatment decisions.

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts ...

A research team from the Department of Pathology at the University of Hong Kong's LKS Faculty of Medicine (HKUMed) has ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie’s latest clinical study, officially titled ‘A ...

Results from the TALENTACE trial suggest that atezolizumab plus bevacizumab and on-demand TACE may be a “new and effective treatment option,” according to Guohong Han, MD, PhD.

Sirtex Medical announced that it has received an expanded CE Mark approval for SIR-Spheres yttrium-90 (Y90) resin microsphere ...

Primary liver cancer is the third leading cause of cancer-related deaths, of which hepatocellular carcinoma (HCC) accounts for approximately 90% of ...

Combining TACE and SBRT offers a promising treatment for large HCC tumors, addressing TACE's limitations in intermediate-stage cases. Technological advancements have improved SBRT's precision and ...